Celcuity's PI3K/AKT/mTOR Inhibitor Shows Clinically Meaningful Survival Benefit in Breast Cancer Trial

Event summary

  • Celcuity's Phase 3 VIKTORIA-1 trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in PIK3CA mutant HR+/HER2- advanced breast cancer patients treated with gedatolisib plus fulvestrant, with or without palbociclib, compared to alpelisib and fulvestrant.
  • A secondary analysis of gedatolisib plus fulvestrant alone also showed a statistically significant and clinically meaningful improvement in PFS compared to alpelisib and fulvestrant.
  • Celcuity intends to submit data to the FDA for a supplemental New Drug Application (sNDA) and to other regulatory authorities.
  • The FDA has granted Priority Review to Celcuity’s NDA for gedatolisib in patients with HR+/HER2-/PIK3CA wild-type ABC, with a PDUFA goal date of July 17, 2026.

The big picture

Celcuity's results address a significant unmet need in advanced breast cancer, where existing therapies targeting PI3Kα or AKT have demonstrated limited efficacy and often lead to resistance. The demonstrated efficacy of a multi-target PAM inhibitor like gedatolisib, particularly in the PIK3CA mutant cohort, represents a potential paradigm shift in treatment approaches. The company's broader strategy to expand gedatolisib's application could unlock significant additional revenue streams, but also introduces increased development risk.

What we're watching

Regulatory Risk
The FDA’s review of the sNDA will be critical; any unexpected requests for additional data or concerns about safety could delay or impact approval.
Commercial Adoption
The success of gedatolisib will depend on physician and patient adoption, which will be influenced by its pricing, reimbursement, and the availability of companion diagnostics to identify eligible patients.
Pipeline Expansion
Celcuity's stated intention to explore gedatolisib for other cancer types and patient populations will be a key indicator of the drug’s long-term commercial potential and the company’s strategic direction.

Related topics

Drug Development Biotechnology